EBNK-001

· Essen Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EBNK-001, covering 2026-02-18 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors [Phase 1, Phase 2]